LEXINGTON, Mass.--(BUSINESS WIRE)--EPIX Pharmaceuticals, Inc. (NASDAQ:EPIX) today reported financial results for the second quarter ended June 30, 2007. “We are very pleased by our achievement this quarter of several corporate goals, including the promising results from our Phase 1b clinical trial of PRX-07034 in both cognitive function and obesity and greater clarity regarding the regulatory path forward for Vasovist,” said Michael G. Kauffman, M.D., Ph.D., chief executive officer of EPIX.
